Compugen Posts Zero Q1 Revenue Amid R&D Spending Slide and Flat Loss | GenomeWeb
NEW YORK (GenomeWeb News) — Compugen today reported it earned no revenue for the first quarter as R&D spending decreased 7 percent and net loss remained flat.
 
The company reported $200,000 in revenue for the first quarter last year.
 
Compugen said R&D spending in the quarter dipped to $2.5 million from $2.7 million year over year.
 
Net loss for the quarter increased slightly to $3.11 million from $3.09 million last year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.